Alnylam Pharmaceuticals’ stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a ...

In her inaugural earnings call as the new CEO of Sanofi, Belén Garijo—until recently head honcho at Germany’s Merck KGaA—laid out her ambitions for the French pharma juggernaut, plainly addressing the ...

Regeneron’s cut from the Dupixent sales boom was $2.11 billion in the quarter, which topped analysts’ consensus by $358 ...

Amgen, LeBron James and world’s top-subscribed YouTuber MrBeast may sound like a Mad Lib of unrelated influences, but the ...

Eli Lilly has doubled down on its partnership with CDMO Resilience as the companies embark on a $750 million investment to ...

Investors anxiously waiting for Bristol Myers Squibb’s key Alzheimer’s disease psychosis readout for Cabenfy will have to ...

Despite Robert F. Kennedy Jr. ultimately agreeing to divest referral fees tied to litigation around Merck & Co.’s HPV vaccine ...

The FDA has rebuked Viatris for a direct-to-consumer (DTC) video that allegedly misled viewers about a cystic fibrosis ...

With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis (MS) portfolio, Biogen is once again positioned for a “growth story,” CEO Chris Viehbacher said ...

As Teva proceeds down the more muted growth path that it telegraphed early this year, the generics and innovative medicines ...

A favorable regulatory resolution with federal health authorities is clearing the way for Incyte’s Opzelura cream to reach ...

Consider it a new supercharged player in the AI marketing game.  | The Considered+AI is an AI-native agency that's been ...